Latest Breaking News On - Akebia therapeutics inc - Page 8 : comparemela.com

Akebia Therapeutics, Inc (NASDAQ:AKBA) SVP Steven Keith Burke Sells 24,311 Shares

Akebia Therapeutics, Inc (NASDAQ:AKBA) SVP Steven Keith Burke Sells 24,311 Shares
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Steven keith burkeMackenzie financial corpArcher investment corpAkebia therapeutics incSapient capitalAkebia therapeutics company profileCitigroup incRaymond james associatesAkebia therapeuticsGet free reportKeith burkeTherapeutics trading downInvestment corpFinancial corpAkebia therapeutics daily

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney.

United kingdomUnited statesNik grundRichard malabreAkebia therapeutics incChief commercial officerChief accountingNasdaq listing ruleAkebia therapeutics

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRichard malabreNik grundMercedes carrascoAkebia therapeutics incChief commercial officerChief accountingNasdaq listing rule

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNik grundMercedes carrascoRichard malabreAkebia therapeutics incChief commercial officerChief accountingNasdaq listing rule

Renal Anemia Therapeutics Market to Record Growth of USD 2 08 billion from 2023 to 2028, Akebia Therapeutics Inc and Amgen Inc to emerge as Some of the Key Companies

/PRNewswire/ The renal anemia therapeutics market is estimated to grow by USD 2.08 billion during 2023-2028, growing at a CAGR of 7.59%. Akebia Therapeutics.

United kingdomCovis pharma gmbJesse maidaAkebia therapeutics incDaiichi sankyo coPharmaceticals coGlaxosmithkline plcKirin holdings coFibrogen incF hoffmann la roche ltdPfizer incBayer agAstellas pharma incTravere therapeutics incSun pharmaceutical industries ltdTechnavio research